Open this publication in new window or tab >>2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Hemodialysens och hemodialysaccessens påverkan på hjärtat
Abstract [en]
Background: Patients on haemodialysis have an increased risk for cardiovascular morbidity and premature mortality. This is attributable to both a high burden of traditional risk factors and risk factors associated with kidney failure and the haemodialysis treatment itself. Ultrafiltration and the haemodynamic burden imposed by arteriovenous vascular access is two haemodialysis specific, potentially modifiable risk factors.
Aims: This thesis explores how haemodialysis and haemodialysis access affect cardiac function. The first aim was to examine how the cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive cardiac Troponin T (TnT) and B-type natriuretic peptide (BNP) are affected by haemodialysis with different dialysers. The second aim was to evaluate if the increase in cardiac biomarkers seen during haemodialysis could be attenuated by changing the ultrafiltration rate. Regarding haemodialysis access, the aim was to study patient specific factors associated with the choice of haemodialysis access and how different access locations and blood flow impact the incidence of heart failure.
Methods: Study I was a prospective, randomised, crossover study. Each patient underwent one session with a low-flux dialyser and one with a high-flux dialyser. Blood samples were collected before treatment, after 180 minutes and at the end of treatment. Using the results from study I, study II was designed as a prospective, crossover, multicentre study. Haemodialysis patients with interdialytic weight gain (IDWG) of more than 2.5% of body weight and an ultrafiltration rate over 0.72 IDWG/h were included. Each participant underwent one session with ordinary dialysis prescription, and one with prolonged treatment time. The goal was to achieve at least a 20% reduction of ultrafiltration rate or ultimately an ultrafiltration rate below 0.6 IDWG/h.
Paper III is a case report describing a patient with highly elevated NT-proBNP caused by a high flow, upper arm arteriovenous fistula (AVF).
Studies IV and V used a retrospective cohort design based on registry data from the Swedish Renal Registry (SRR) and the National Patient Register (NPR). All patients who had a new haemodialysis access registered in the SRR 2013-2022 were included in study IV. In study V, prevalent haemodialysis patients and patients with pre-existing heart failure were excluded. Factors associated with choice of access and subsequent risk of heart failure were assessed in relation to access location and access flow.
Results: Study I included 31 adult, stable haemodialysis patients. Both NT-proBNP and TnT increased during haemodialysis (p<0.001 for both). However, this increase was masked during haemodialysis with high-flux dialyser.
Study II, including 41 patients, confirmed the results from study I (p<0.001 for both markers). However, there was no difference in the increase of cardiac markers between sessions with different ultrafiltration rates (p=0.967 for NT-proBNP and p=0.823 for TnT).
The case reported in Paper III demonstrated that ligation of a high flow arteriovenous fistula can reverse heart failure symptoms and greatly reduce NT-proBNP levels.
In study IV, data on 9706 patients and 17709 accesses was included. The proportion of upper arm fistulas (p=0.042) and arteriovenous grafts (p=0.007) created increased, whilst the proportion of forearm fistulas decreased (p<0.001) during the study period. Factors associated with the choice of haemodialysis access were mainly factors associated with vessel size and vessel quality. In study V, 6579 patients with 11238 accesses were included. There was no difference in risk of heart failure development when comparing different arteriovenous accesses (upper arm AVF HR 0.957 95% CI 0.821-1.115, p=0.57, arteriovenous graft HR 1.044 95% CI 0.842-1.294, p=0.70 with forearm AVF as reference). The risk of heart failure associated with access flow was U-shaped (p<0.001 for non-linearity).
Conclusion: Performing haemodialysis causes cardiac strain that can be measured as increase of cardiac markers. However, reducing the ultrafiltration rate in patients that tolerates their ordinary treatment, does not attenuate this effect. High flow fistulas can cause heart failure, and the use of upper arm fistulas is increasing. The risk of heart failure development is strongly associated with comorbidities. Flow, but not access location itself, impacts heart failure development.
Place, publisher, year, edition, pages
Umeå: Umeå University, 2026. p. 53
Keywords
Haemodialysis, Haemodialysis access, Cardiac biomarkers, Heart failure
National Category
Nephrology
Identifiers
urn:nbn:se:umu:diva-258534 (URN)978-91-6850-067-6 (ISBN)978-91-6850-068-3 (ISBN)
Public defence
2026-10-23, Hörsal Betula, Norrlands universitetssjukhus, Umeå, 13:00 (Swedish)
Opponent
Supervisors
2026-10-022026-09-282026-10-13Bibliographically approved